Scarica l'app Stockscreener
1.08
9.90%
0.0973
Precedente Chiudi:
$0.9827
Aprire:
$1
Volume 24 ore:
6.00M
Relative Volume:
6.41
Capitalizzazione di mercato:
$206.03M
Reddito:
$4.71M
Utile/perdita netta:
$-58.01M
Rapporto P/E:
-1.3116
EPS:
-0.8234
Flusso di cassa netto:
$-46.68M
1 W Prestazione:
+10.42%
1M Prestazione:
+13.08%
6M Prestazione:
-4.42%
1 anno Prestazione:
-14.29%
Intervallo 1D:
$0.997
$1.08
Intervallo di 1 settimana:
$0.9574
$1.08
Portata 52W:
$0.90
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Nome
Lucid Diagnostics Inc
Settore
Industria
Telefono
212 949 4319
Indirizzo
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.08 | 206.03M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Iniziato | BTIG Research | Buy |
| 2021-11-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Needham | Buy |
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lucid Diagnostics Inc (LUCD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lucid Diagnostics Inc (LUCD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey
Lucid Diagnostics Inc (LUCD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lucid Diagnostics Inc (LUCD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lucid Diagnostics Inc (LUCD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Certain Stock Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2026. - marketscreener.com
Lucid Diagnostics misses on revenue, but 2026 growth outlook lights up bull case - MSN
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case - Benzinga
LUCD Maintained by Ascendiant Capital -- Price Target Raised to $9.25 - GuruFocus
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results - Yahoo Finance
Lucid Diagnostics Q1 2026 Earnings: EPS Miss Widens as Company Reports Wider-Than-Expected LossProfit Inflection Point - newsline.com
LUCD Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue Stage ChallengesRevenue Warning Signal - The Legal Advocate
LUCD Stock Price, Quote & Chart | LUCID DIAGNOSTICS INC (NASDAQ:LUCD) - ChartMill
LUCD - Finviz
Lucid Diagnostics (LUCD) Surges 7% as Momentum Builds Near Key ResistanceTurnaround Stocks - The Legal Advocate
Lucid Diagnostics Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Firm Advances Commercial Rollout - The Legal Advocate
Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market - Stock Titan
Lucid Diagnostics (LUCD) Rallies +1.30% as Bulls Target $1.02 2026-05-19Dividend Growth Stocks - The Legal Advocate
Lucid Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-05-17 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates - MSN
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ... By GuruFocus - Investing.com Canada
Upcoming Events - FinancialContent
Maxim Group Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
BTIG Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $2.5 - Moomoo
PAVmed (PAVM) Q1 2026 Earnings Transcript - AOL.com
PAVmed (PAVM) Q4 2025 Earnings Transcript - The Globe and Mail
PAVmed Reports Q1 2026 Financial Results, Highlights Progress in Veris Health FDA Submission and Lucid Diagnostics Commercial Expansion - Minichart
Earnings Call Summary | Lucid Diagnostics(LUCD.US) Q1 2026 Earnings Conference - 富途牛牛
PAVmed Reports Wider-than-Expected Q1 2026 Loss - AlphaStreet
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains By Investing.com - Investing.com Australia
Q1 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2026 Earnings Call Transcript - Insider Monkey
PAVmed (NASDAQ: PAVM) Q1 2026 results, losses and cash position - Stock Titan
PAVmed Q1: cancer test and implantable monitor push toward coverage, FDA - Stock Titan
Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD) - The Globe and Mail
Lucid says $44.8M pro forma cash extends runway well into 2027 as it awaits Medicare LCD - MSN
Lucid Diagnostics Inc.Common Stock (NQ: LUCD - FinancialContent
PAVmed Inc.Series Z Warrant (NQ: PAVMZ - FinancialContent
Lucid Diagnostics Earnings Call Balances Progress, Pressure - TipRanks
PAVmed Reports Business Expansion and Financial Update - Intellectia AI
PAVmed (NASDAQ: PAVM) posts Q1 2026 loss and flags going concern risks - Stock Titan
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Lucid Diagnostics Releases Q1 2026 Financial Results - AlphaStreet
LUCD Q1 2026 Earnings Transcript - The Globe and Mail
Lucid Diagnostics Q1 Earnings Call Highlights - Yahoo Finance
LUCD: Q1 revenue reached $1.3M on 3,177 tests, with cash runway extended and Medicare approval pending - TradingView
Lucid Diagnostics Reports Q1 2026 Financial Results: $1.3M Revenue, Strong Cash Position, and Medicare Reimbursement Milestone Progress - Minichart
Lucid Diagnostics Inc Azioni (LUCD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lucid Diagnostics Inc Azioni (LUCD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
Aug 20 '25 |
Buy |
1.02 |
100,000 |
101,840 |
665,443 |
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):